First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA

Transthyretin-Mediated Amyloidosis Cardiomyopathy The FDA has just approved the very first treatment for hereditary or wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).  ATTR-CM is a rare disease that occurs when amyloids, an…

Continue Reading First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA